REGENXBIO Hits Duchenne Milestone | Zhimeng Launches ALS Pivotal Trial – Clinical News Update

AbbVie Files FDA NDA for Tavapadon | New Givinostat Data in DMD Unveiled – Clinical News Update

Otsuka Reports Breakthrough Phase 3 Kidney Data | AusperBio Starts Hepatitis B Trial

Ultomiris Shows Promise in IgA Nephropathy | CRENESSITY 2-Year Data Revealed

GC Biopharma Secures IND OK in Korea for COVID-19 mRNA Vaccine Trial

Arletta Pharma Reports Positive Phase II Results | Eli Lilly Ebglyss Shows 4-Year Control

Kidney Drug Expansion Falls Short | Ionis Steps Up Angelman Awareness Campaign

$2M ALS Trial Support Announced | Ionis Wins Breakthrough Status for Zilganersen – Clinical News

Fresenius Kabi Recalls Famotidine Injection

Myrtelle’s Canavan Trial Success | NeuroSense Marks Alzheimer’s Progress – Clinical News Update

Ascletis Picks ASC37 as Lead Oral Triple Agonist – Clinical News Update

ADC Therapeutics to Update on LOTIS-7 Trial – Clinical News Update

Industry Leaders- Media coverage | Lifescience Intellipedia | Chemxpert Database | Clival Database

Gilead HIV Pill Nears Filings | TempraMed Strengthens IP with Korea Patent

MetaVia Presents DA-1726 Data | Nanoscope’s Optogenetic Trial Shows Safety – Clinical News Update

CPP Phase 3 Trial Positive | Edgewise Advances EDG-7500 in Hypertrophic Cardiomyopathy

"PMDA Clears VarmX Phase 1 Waiver | Basilea Secures BARDA Deal for Antibiotic – Clinical News Update

Gefurulimab Succeeds in Phase 3 Trial | GC Biopharma’s Anthrax Vaccine Shines – Clinical News Update

Sobi Shows Positive EMBRACE Data | US FDA Grants Breakthrough Tag to Sanofi

AIDS 2026: Cabenuva Beats Daily HIV Therapy | MannKind Advances IPF Drug

Altimmune Reports Strong MASH Data | GSK Shows Positive Phase 3 Hepatitis B Results

Atavistik Bio Expands Rare Disease Program with Cure HHT Partnership

Sanofi Updates Phase 3 CIDP Study | Novartis Hits FSHD Trial Milestone

Japan Reviews GSK’s Hep B Drug | Neurizon Starts NUZ-001 HEALEY ALS Study

Sanofi Lunsekimig Hits Phase 2 Goals | Health Canada Clears Affinia Therapeutics Trial

Novartis Wins EU Approval for Rhapsido | AbbVie Files SKYRIZI Update

Gilead & Merck Show Success for Weekly HIV Pill | Caliway Unveils ADA Data

Lundbeck Completes Enrollment in Phase 3 MASCOT Trial Ahead of Schedule

Tremfya Delivers Strong Crohn’s Data | Alebund Finishes Global Phase 3 Trial

Roche Advances Obesity Pipeline | Johnson & Johnson Reports Positive Lupus Data

Eli Lilly’s Orforglipron Tops Oral Semaglutide | FDA Reviews Vanda’s Imsidolimab

Energenesis Highlights DFU Therapy at EWMA 2026 | Viking VK2735 Gains Momentum

EyePoint DURAVYU Clears Safety Review | REGENXBIO Shows Phase 3 Success

Aplagon Doses First Patient in Phase 2a APAC Trial | Meiji Seika Pharma Starts Phase 1 Study

Hengrui Pharma & Braveheart Bio Report Positive Phase 2 Data | Myrtelle Updates MYR-101

Hoth Therapeutics Reports Positive MASLD Data | POLY-ACS Trial Highlights Polypill Strategy